Opexa Granted Four New Patents for MS Treatment

Opexa Therapeutics announced the issuance of four new patents covering its broad T-cell immunotherapy platform earlier this week, bringing its total portfolio, including in-licensed patents, to 160. This latest expansion strengthens the company's IP position surrounding Tcelna, a personalized T-cell immunotheraphy in development for treatment of secondary progressive multiple sclerosis.